Kunpeng Wu
Xiaoyan Zhu2- 1Department of Oncology, Heyuan Hospital of Guangdong Provincial People’s Hospital, Heyuan People’s Hospital, Heyuan, China
- 2Department of Otorhinolaryngology, Heyuan Hospital of Guangdong Provincial People’s Hospital, Heyuan People’s Hospital, Heyuan, China
- 3Department of Radiology, Heyuan Hospital of Guangdong Provincial People’s Hospital, Heyuan People’s Hospital, Heyuan, China
- 4Department of Pathology, Heyuan Hospital of Guangdong Provincial People’s Hospital, Heyuan People’s Hospital, Heyuan, China
Background: Primary Ewing’s sarcoma of sphenoid sinus, observed in children and adolescents, is an extremely rare malignancy. Such rarity makes the imaging features and treatment strategies for Ewing’s sarcoma of sphenoid sinus unclear. This study aimed to offer guidance for treating this very disease by describing a patient with a rare primary Ewing’s sarcoma of sphenoid sinus and reviewing the available data in the literature.
Case description: A case of Ewing’s sarcoma in sphenoid sinus treated with multidisciplinary treatment approaches, including tumor resection, radiotherapy, chemotherapy, and antiangiogenic therapy, was presented in this study. Moreover, literature for Ewing’s sarcoma in the head was systematically searched, and two cases in the sphenoid sinus and five cases in the sphenoid bone were identified. Furthermore, the clinical features, imaging findings, pathological characteristics, treatment, and prognosis were summarized.
Conclusion: Tumor resection combined with radiotherapy and chemotherapy may provide favorable results for patients with Ewing’s sarcoma of sphenoid sinus and bone. However, more reports are still necessary to further clarify optimal management.
Introduction
Ewing’s sarcoma is an aggressive bone tumor, and ranks second only to osteosarcoma as the most common malignancy in children and young adults (1). It predominately occurs in the shafts of the long bones, the pelvic bones, ribs, and spine, comprising 70% of all Ewing’s sarcoma cases (2). Primary Ewing’s sarcoma can be rarely detected in the head and neck region, especially in sphenoid sinus (3). Few literatures on the case of primary Ewing’s sarcoma in sphenoid sinus were ever reported. Thus, a case of a 26-year-old male patient with primary Ewing’s sarcoma of sphenoid sinus was presented (Figure 1).
Figure 1 Treatment course of the case in a timeline (MRI: magnetic resonance imaging; CR: complete response; PR: partial response; V: vincristine; D: doxorubicin; C cyclophosphamide; I: ifosfamide; and E: etoposide).
Case report
In May 2021, a 26−year−old man underwent an otorhinolaryngological clinical examination due to a history of intermittent right blepharoptosis and facial swelling; he had had these symptoms for 9 months. He was detected to have a mildly tender firm swelling in the right temporal region, and the eye movement, visualization, mouth opening, and airway were within normal limits. The patient had a history of occasional smoking, but no trauma, infection, or previous medical history, as well as an unremarkable family history. The blood routine examination, usual biochemical tests, and tumor biomarkers were also within normal limits. The computed tomography (CT) scan showed an inhomogeneous mass in the right sphenoid sinus cavity, and steolytic bone destruction and defect in the parietal wall of sphenoid sinus (Figure 2). Contrast magnetic resonance imaging (MRI) was then used to determine the extent of the tumor, and displayed a solid mass in the right sphenoid sinus that had extended into the right orbital apex and posterior ethmoid sinus (Figure 3). Contrast material-enhanced CT of the whole body was performed to exclude tumor distant metastasis. Based on preoperative imaging study findings, the otolaryngologist initially considered it a nonmalignant mass. Subsequently, the patient underwent otorhinolaryngological surgical removal of the lesion, when the intraoperative frozen specimen suggested a small round cell tumor, and the diagnosis of malignancy could not be clearly defined. The tumor was partially resected, but given that an attempt at radical resection was associated with high risks of intraoperative massive bleeding and visual impairment, the part of the tumor that adheres severely to the optic nerve sheath and the cavernous sinus was not resected. Postoperative histopathological examination showed that the tumor cells were small oval or round with scanty cytoplasm, and round or oval vesicular nuclei (Figures 4A, B). Immunohistochemistry revealed membranous positivity for CD99 (Figures 4C, D), diffuse nuclear positivity for NKX2.2, diffuse cytoplasmic positivity for vimentin and sporadic positivity for Syn and EMA, strongly suggesting a diagnosis of Ewing’s sarcoma. In this case, the tumor cells were immunohistochemically negative staining for CK, LCA, CgA, CD56, P40, CK7, CK5/6, IMP3, S100, GFAP, HMB45, and SOX10, respectively. The pathological diagnosis was confirmed by two pathologists. After surgery, his intermittent right blepharoptosis and facial swelling disappeared. The contrast MRI was conducted to evaluate the tumor status, and a residuary tumor was detected in the surgical area (Figure 5). The multidisciplinary consultation meeting was conducted for making postoperative courses.
Figure 2 Preoperative CT examination of the paranasal sinus. The CT examination showed an inhomogeneous mass in the right sphenoid sinus cavity, and steolytic bone destruction and defect in the parietal wall of sphenoid sinus. (A) Sagittal image and (B) coronal image. (The mass is marked with a black arrow.).
Figure 3 Preoperative MR examination of the paranasal sinus. The MR examination detected a solid mass in the right sphenoid sinus that had extended into the right orbital apex and posterior ethmoid sinus. (A) Axial T1-weighted image. (B) Axial T2-weighted image. (C) Axial T1-weighted enhanced image. (D) Sagittal T1-weighted enhanced image. (E) Coronal T1-weighted enhanced image. (The mass is marked with a black arrow.).
Figure 4 Histological and immunohistochemical features of the tumor of sphenoid sinus. (A, B) Hematoxylin and eosin (H & E) staining of a tumor specimen showing small round atypical cells with densely stained chromatin and high nuclear cytoplasmic ratios. (B, C) Immunohistochemical staining of a tumor specimen showing diffuse positive staining for CD99 on the tumor cell membrane. (A, C): Original magnification × 100; B, D: Original magnification × 400.).
Figure 5 Postoperative MR examination of the paranasal sinus. The MR examination detected a residuary tumor in the surgical area and the lateral side and the tip of the right orbit. (A) Axial T1-weighted image. (B) Axial T2-weighted image. (C) Axial T1-weighted enhanced image. (D) Sagittal T1-weighted enhanced image. (E) Coronal T1-weighted enhanced image. (The mass is marked with a black arrow.).
To reduce the radioactive exposure of the right eye, the patient was arranged to undergo chemotherapy with alternating cycles of doxorubicin (75 mg/m2 on day 1), vincristine (2 mg on day 1), cyclophosphamide (1,200 mg/m2 on day 1), and ifosfamide (1,800 mg/m2 on days 1–5) plus etoposide (100 mg/m2 on days 1–5) every 3 weeks before proceeding with the radiotherapy. Unfortunately, the response evaluation criteria in solid tumors (RECIST) criteria confirmed the residuary tumor as a stable disease after two cycles of postoperative chemotherapy. Then, intensity-modulated radiotherapy [gross target volume (GTV) 5,600 centigray (cGy)/28 fractions, clinical target volume (CTV) 5,040 cGy/28 fractions, with details summarized in Figure 6] and anti-angiogenic therapy (anlotinib, 10 mg on days 1–14, every 3 weeks) were conducted on the basis of chemotherapy. The patient experienced certain treatment–related toxicities, including anorexia, nausea, vomit, fatigue, diarrhea, leucopenia, neutropenia, alanine aminotransferase concentration increase, and aspartate aminotransferase concentration increase, within grade 3. After 4 weeks of radiotherapy, there was a complete remission of the tumor by the RECIST criteria (Figure 7). Twelve months after the diagnosis, the patient remained recurrence−free and regained his high-quality life.
Figure 6 Dose planning of radiotherapy. Planned target volume (GTV: red, PGTV: pink, CTV: light blue, and PTV: blue) covered by the 95% isodose can be seen in axial (A), coronal (C), and sagittal (D) planes on pretreatment planning computed tomography. (B) The dose-volume histogram showed that 95% of the PGTV and PTV volumes irradiated with more than 5,040 cGy and 5,600 cGy.
Figure 7 Postradiotherapy MR examination of the paranasal sinus. The MR examination detected a complete remission of the tumor. (A) Axial T1-weighted image. (B) Axial T2-weighted image. (C) Axial T1-weighted enhanced image. (D) Sagittal T1-weighted enhanced image. (E) Coronal T1-weighted enhanced image.
Discussion
Ewing’s sarcoma was first described as “diffuse endothelioma of bone” by James Ewing in 1921 (4). Generally, the majority of Ewing’s sarcoma is observed in the diaphysis or metadiaphyseal region of long bones. However, primary Ewing’s sarcoma is extremely rare in the head and neck region, accounting for merely 1% to 9% (5–8). In addition, the most common sites for Ewing’s sarcoma of the head and neck are the mandible and skull base, followed by the orbital roof, maxilla, and nasal cavities (5–8). Meanwhile, the most common symptoms are presented as painful mass, swelling, headaches, visual problems, and congestion/obstruction (5–8). Based on retrospective analysis, age, clinical stage, tumor site, and the response to systemic chemotherapy are important prognostic factors for disease-free survival and overall survival in patients with Ewing’s sarcoma of the head and neck (3, 6). Like the treatment for skeletal Ewing’s sarcoma, induction chemotherapy and local control (surgical resection ± radiotherapy) are the frequently adopted treatment approaches for Ewing’s sarcoma in the head and neck, followed by adjuvant chemotherapy (9, 10).
In the present study, a case of primary Ewing’s sarcoma in sphenoid sinus was investigated. Limited by small patient series, there was no retrospective study about Ewing’s sarcoma of sphenoid sinus. The Springer, Elsevier, Wiley, MEDLINE, and EMBASE databases were systematically searched to March 2022. Given that the case of primary Ewing’s sarcoma in sphenoid sinus was rarely reported, a literature review was hereby presented. Only two cases of primary Ewing’s sarcoma in sphenoid sinus (11, 12) and five cases in the sphenoid bone (13–18) were found in the published articles. As shown in Table 1, the onset age and sex ratio of these cases resemble the status of overall Ewing’s sarcoma. All cases with primary Ewing’s sarcoma in sphenoid sinus and bone were diagnosed with non-metastatic disease, which might be attributed to early clinical symptoms and limited growth space. Meanwhile, diminution of vision, proptosis, headache, and swelling were found to be the most common symptoms (11–14, 16–18). In addition, a diffuse and strong membranous staining pattern for CD99 was universally considered as a highly sensitive and useful immunohistochemical biomarker for Ewing’s sarcoma (19, 20). In system treatment, surgical excision of the tumor combined with radiotherapy and chemotherapy was considered an appropriate treatment for Ewing’s sarcoma of sphenoid sinus and bone (9, 10), while in local treatment, surgical excision and radiotherapy are the main strategies (21). The limitation of the anatomy of sphenoid bone and sinus makes it difficult for tumor excision to achieve enough safe surgical margins (9, 10). Thus, radiotherapy is considered as an effective postoperative treatment for improving local control (22, 23), which can also be adopted to replace surgical excision for patients unsuitable for surgery (22, 23). Vincristine, isofosfamide/cyclophosphamide, doxorubicin, etoposide, and actinomycin-D are the most frequently used drugs in cytotoxic chemotherapy (24). Based on guidelines of Ewing’s sarcoma available in the 2021 National Comprehensive Cancer Network (NCCN), ifosfamide and etoposide alternating with the standard regimen of vincristine, doxorubicin, and cyclophosphamide (VDC-IE) has become a standard for Ewing’s sarcoma patients, and multiagent chemotherapy should be performed at least 9 weeks prior to local therapy. As shown in Table 1, given the lack of preoperative biopsy, preoperative chemotherapy was not conducted in these cases. Interestingly, poor response to chemotherapy was observed in primary Ewing’s sarcoma of sphenoid sinus. Negru et al. showed that the patient with Ewing’s sarcoma of sphenoid sinus was identified as local disease progression by MRI after three cycles of first−line chemotherapy (VID:; vincristine, isofosfamide, and doxorubicin) (11). Furthermore, Turki et al. suggested that the tumor did not respond to chemotherapy (VIDE; vincristine, isofosfamide, doxorubicin, and etoposide) and the patient died after three cycles of chemotherapy (12). In the hereby proposed case, the patient was confirmed to have stable disease after two cycles of postoperative chemotherapy (VDC-IE: vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide), and radiotherapy was therefore performed, followed by anti-angiogenic therapy (anlotinib, a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors 2 and 3, fibroblast growth factors 1–4, platelet-derived growth factor receptor α and β, c-Kit, and Ret, applicable to the treatment of soft-tissue sarcoma in China (25, 26)). The poor chemosensitivity for Ewing’s sarcoma of sphenoid sinus was preliminarily attributed to lack of rich tumor blood supply in comparison to Ewing’s sarcoma of long bones. Indeed, the prognosis for patients with primary Ewing’s sarcoma in sphenoid sinus and bone is still unclear, and patients with Ewing’s sarcoma of the head and neck region tend to have favorable prognosis compared with those with Ewing’s sarcoma of the proximal extremity or axial skeleton (27). It can be observed from Table 1 that patients capable of completing the treatment plan might achieve adequate long-term prognosis and cure.
Table 1 Primary Ewing’s sarcoma of sphenoid sinus and bone in the literature.
The limitations of this study were as follows: (i) a biopsy should be obtained for histopathological diagnosis to confirm Ewing’s sarcoma after imaging examination; (ii) the use of preoperative chemotherapy may increase the rate of complete surgical resection; and (iii) these genetic changes (EWS and FLI1) can be detected with cytogenetics, fluorescence in situ hybridization, polymerase chain reaction, and gene sequencing.
In conclusion, primary Ewing’s sarcoma rarely occurs in sphenoid bone and sinus. Multidisciplinary therapy consisting of an initial biopsy, complete surgical resection, aggressive combination chemotherapy, and localized radiotherapy should be acknowledged as the most beneficial treatment strategy for Ewing’s sarcoma of sphenoid bone and sinus and results in long-term survival.
Ethics statement
Written consent for publication of this case report and the accompanying images was obtained from the patient.
Author contributions
KW and ZL designed and wrote the report; KW, JW, YZL, and YunL collected the clinical data of radiotherapy and chemotherapy; XZ collected the clinical surgery data; DW and HW performed pathological diagnosis and collected pathological pictures; and YanL provided the imaging report and collected imaging pictures. All authors contributed equally to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
CT, Computed tomography; MRI, Magnetic resonance imaging; FISH, Fluorescence in situ hybridization; IHC, Immunohistochemistry; RECIST, Response evaluation criteria in solid tumors; NCCN, National Comprehensive Cancer Network; CTV, Clinical target volume;GTV, Gross target volume; cGy, Centigray; CR, Complete response; PR, Partial response.
References
1. Zollner SK, Amatruda JF, Bauer S, Collaud S, de Alava E, DuBois SG, et al. Ewing Sarcoma-diagnosis, treatment, clinical challenges and future perspectives. J Clin Med (2021) 10(8):1685. doi: 10.3390/jcm10081685
2. Grunewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Alava E, Kovar H, et al. Ewing Sarcoma. Nat Rev Dis Primers (2018) 4(1):5. doi: 10.1038/s41572-018-0003-x
3. Grevener K, Haveman LM, Ranft A, van den Berg H, Jung S, Ladenstein R, et al. Management and outcome of Ewing sarcoma of the head and neck. Pediatr Blood Cancer (2016) 63(4):604–10. doi: 10.1002/pbc.25830
5. Siegal GP, Oliver WR, Reinus WR, Gilula LA, Foulkes MA, Kissane JM, et al. Primary ewing's sarcoma involving the bones of the head and neck. Cancer (1987) 60(11):2829–40. doi: 10.1002/1097-0142(19871201)60:11<2829::AID-CNCR2820601139>3.0.CO;2-S
6. Allam A, El-Husseiny G, Khafaga Y, Kandil A, Gray A, Ezzat A, et al. Ewing's sarcoma of the head and neck: A retrospective analysis of 24 cases. Sarcoma (1999) 3(1):11–5. doi: 10.1080/13577149977811
7. Carlotti CG Jr., Drake JM, Hladky JP, Teshima I, Becker LE, Rutka JT. Primary ewing's sarcoma of the skull in children. utility of molecular diagnostics, surgery and adjuvant therapies. Pediatr Neurosurg (1999) 31(6):307–15. doi: 10.1159/000028881
8. Desai KI, Nadkarni TD, Goel A, Muzumdar DP, Naresh KN, Nair CN. Primary ewing's sarcoma of the cranium. Neurosurgery (2000) 46(1):62–8. doi: 10.1093/neurosurgery/46.1.62
9. Thorn D, Mamot C, Krasniqi F, Metternich F, Prestin S. Multimodality treatment in ewing's sarcoma family tumors of the maxilla and maxillary sinus: Review of the literature. Sarcoma (2016) 2016:3872768. doi: 10.1155/2016/3872768
10. Whaley JT, Indelicato DJ, Morris CG, Hinerman RW, Amdur RJ, Mendenhall WM, et al. Ewing Tumors of the head and neck. Am J Clin Oncol (2010) 33(4):321–6. doi: 10.1097/COC.0b013e3181aaca71
11. Negru ME, Sponghini AP, Rondonotti D, Platini F, Giavarra M, Forti L, et al. Primary ewing's sarcoma of the sinonasal tract, eroding the ethmoid and sphenoid sinus with intracranial extension: A rare case report. Mol Clin Oncol (2015) 3(4):807–10. doi: 10.3892/mco.2015.548
12. Turki S, Kedous S, Mahjoubi M, Dhambri S, Attia Z, Touati S. Primary ewing's sarcoma of the sphenoid sinus with orbital and intracranial extension: a case report. Tunis Med (2016) 94(11):687.
13. Varan A, Caner H, Saglam S, Buyukpamukcu M. Primary ewing's sarcoma of the sphenoid bone: a rare presentation. Pediatr Radiol (1998) 28(5):311. doi: 10.1007/s002470050360
14. Sharma RR, Netalkar A, Lad SD. Primary ewing's sarcoma of the greater wing of the sphenoid bone. Br J Neurosurg (2000) 14(1):53–6. doi: 10.1080/02688690042933
15. Singh P, Jain M, Singh DP, Kalra N, Khandelwal N, Suri S. MR findings of primary ewing's sarcoma of greater wing of sphenoid. Australas Radiol (2002) 46(4):409–11. doi: 10.1046/j.1440-1673.2002.01086.x
16. Apostolopoulos K, Ferekidis E. Extensive primary ewings' sarcoma in the greater wing of the sphenoid bone. ORL J Otorhinol Relat Spec (2003) 65(4):235–7. doi: 10.1159/000073123
17. Sharma A, Garg A, Mishra NK, Gaikwad SB, Sharma MC, Gupta V, et al. Primary ewing's sarcoma of the sphenoid bone with unusual imaging features: a case report. Clin Neurol Neurosurg (2005) 107(6):528–31. doi: 10.1016/j.clineuro.2004.11.001
18. Singh GR, Choudhary V, Agrawal R. Primary Ewing sarcoma of sphenoid bone with intracranial extension: A common tumour at an uncommon location. J Clin Diagn Res (2017) 11(2):ED15–6. doi: 10.7860/JCDR/2017/23541.9275
19. Choi EY, Gardner JM, Lucas DR, McHugh JB, Patel RM. Ewing Sarcoma. Semin Diagn Pathol (2014) 31(1):39–47. doi: 10.1053/j.semdp.2014.01.002
20. Ozaki T. Diagnosis and treatment of Ewing sarcoma of the bone: a review article. J Orthop Sci (2015) 20(2):250–63. doi: 10.1007/s00776-014-0687-z
21. Eaton BR, Claude L, Indelicato DJ, Vatner R, Yeh B, Schwarz R, et al. Ewing Sarcoma. Pediatr Blood Cancer. (2021) 68 Suppl 2:e28355. doi: 10.1002/pbc.28355
22. Dunst J, Schuck A. Role of radiotherapy in Ewing tumors. Pediatr Blood Cancer. (2004) 42(5):465–70. doi: 10.1002/pbc.10446
23. Donaldson SS. Ewing Sarcoma: radiation dose and target volume. Pediatr Blood Cancer. (2004) 42(5):471–6. doi: 10.1002/pbc.10472
24. Meyers PA. Systemic therapy for osteosarcoma and Ewing sarcoma. Am Soc Clin Oncol Educ Book. (2015) 35:e644–7. doi: 10.14694/EdBook_AM.2015.35.e644
25. Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang G, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res (2018) 24(21):5233–8. doi: 10.1158/1078-0432.CCR-17-3766
26. Xu J, Xie L, Sun X, Liu K, Tang X, Yan T, et al. Anlotinib, vincristine, and irinotecan for advanced Ewing sarcoma after failure of standard multimodal therapy: A two-cohort, phase Ib/II trial. Oncologist (2021) 26(7):e1256–62. doi: 10.1002/onco.13726
Keywords: Ewing’s sarcoma, sphenoid sinus, sphenoid bone, case report, literature review
Citation: Wu K, Zhu X, Li Y, Wen D, Wu H, Lai Y, Li Y, Wu J and Liu Z (2022) Primary Ewing’s sarcoma of sphenoid sinus: A case report and literature review. Front. Oncol. 12:894833. doi: 10.3389/fonc.2022.894833
Received: 12 March 2022; Accepted: 06 June 2022;
Published: 15 August 2022.
Edited by:
Bekir Cinar, Clark Atlanta University, United StatesReviewed by:
Youssef Darouassi, Cadi Ayyad University, MoroccoCopyright © 2022 Wu, Zhu, Li, Wen, Wu, Lai, Li, Wu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kunpeng Wu, 67104234@163.com; Zhuoxing Liu, liuzhuoxing@sina.com